Caribou Biosciences, Inc. (CRBU) stock
CRBUNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3074% below fair value
$0.34−0.01 (-3.43%)
Close on Nov 17, 2026Market cap $36.53MP/E –Yield –
Caribou Biosciences price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Caribou Biosciences's price to sales ratio was 4.1× on Nov 11, 2026, against 19.5× a year earlier. Over the last 5 years it ranged from 4.1× to 112.9×, with a median of 17.3×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 4.1× | −11.9 |
| 2025 | Dec 31, 2025 | 16.0× | +3.4 |
| 2024 | Dec 31, 2024 | 12.5× | −2.1 |
| 2023 | Dec 29, 2023 | 14.6× | −15.5 |
| 2022 | Dec 30, 2022 | 30.1× | −82.8 |
| 2021 | Dec 31, 2021 | 112.9× | – |
See a number that looks wrong?